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Background and aims: In the general population, habitual coffee consumption is inversely 
associated with the metabolic syndrome, a syndrome that is rather common also in patients with 
type 1 diabetes. However, whether coffee intake is beneficially related to the metabolic syndrome 
also in type 1 diabetes, is not known. We, therefore, studied the potential association between 
coffee consumption and the metabolic syndrome in a large population of individuals with type 1 
diabetes. Furthermore, we investigated whether coffee consumption is associated with insulin 
resistance (estimated glucose disposal rate, eGDR), kidney function (estimated glomerular 
filtration rate, eGFR), and low-grade chronic inflammation (high-sensitivity C-reactive protein, 
CRP).  
 
Methods and results: Data from 1040 participants in the Finnish Diabetic Nephropathy Study were 
included in these cross-sectional analyses. Metabolic syndrome was assumed if at least 3 of the 
following cardiovascular risk factors were present: central obesity, high blood pressure, low HDL-
cholesterol concentration, high triglyceride concentration, and hyperglycaemia. Subjects were 
categorized based on self-reported daily coffee intake: non-consumers (<1 cup/d), low (≥1 cups/d 
<3), moderate (≥3 cups/d <5), and high coffee consumption (≥5 cups/d). In multivariable logistic 
regression analysis, moderate and high coffee consumption was associated with increased odds of 
the metabolic syndrome. Moreover, any level of coffee consumption was associated with 
increased risk of the blood pressure-component. An increasing trend was observed in the eGFR 
with increasing coffee consumption.  
 
Conclusions: In type 1 diabetes, high coffee intake is associated with the metabolic syndrome, and 
























The metabolic syndrome (MS) represents a cluster of risk factors for cardiovascular disease [1]. 
Although habitually associated with type 2 diabetes, the MS is also highly prevalent in patients 
with type 1 diabetes (T1D) [2]. Importantly, in this patient group the MS is an independent 
predictor of cardiovascular events, and premature mortality [3]. Therefore, identifying risk factors 
related to the MS is of major importance. 
 
In two meta-analyses, coffee consumption has been inversely related to the MS [4, 5]. Particularly, 
a negative association between coffee consumption and the MS has been most evident in high 
habitual intakes, those exceeding 3 cups of coffee per day [6]. Moreover, long-term coffee 
consumption has been associated with decreased risk of cardiovascular disease [7] and type 2 
diabetes [8]. The beneficial effects of coffee have been attributed to its bioactive components, 
caffeine, diterpenes, phenolic acids, and melanoidins [9]. However, the acute effects seem to 
differ from the observed long-term effects [10] as, in a meta-analysis of observational studies, 
coffee consumption showed no substantial effects on the risk of hypertension, but in a meta-
analysis of randomized controlled trials, an acute rise in blood pressure was reported [5]. 
Moreover, acute reducing effects of coffee on insulin sensitivity have been observed [8, 11]. 
 
To our knowledge, reports on the relationship between habitual coffee consumption and the MS 
in T1D have not been published. Our aim was, therefore, to fill in this gap in knowledge. 
Furthermore, we investigated the association between coffee consumption and insulin sensitivity, 
assessed by the estimated glucose disposal rate (eGDR), and low-grade chronic inflammation, 
examined by high-sensitivity C-reactive protein (hsCRP). As subclinical inflammation is related to 
the progression of diabetic nephropathy [12], the association between coffee intake and the 




Subjects were participants of the Finnish Diabetic Nephropathy (FinnDiane) Study, which aims to 















were all individuals with known MS status and a completed diet questionnaire (n=1040, age 46.7 ± 
0.4 years, 45% men). Individuals with end-stage renal disease (dialysis or renal transplant) or eGFR 
<30 mmol/l were excluded. T1D was defined as onset of diabetes before the age of 35 years and 
permanent insulin therapy started within one year of the diagnosis. All participants signed an 
informed consent prior to study participation. The protocol was approved by the Ethics Committee 
of the Helsinki and Uusimaa Hospital District.  
 
At the study visit, blood pressure was measured twice in the sitting position following a 10-minute 
rest. A mean of the two measurements was calculated. Weight and height were measured in light 
clothing without wearing shoes, and body mass index (kg/m
2
) was calculated. Waist circumference 
was measured at the midway between the lowest rib and iliac crest. The attending physician 
recorded data on medication use and diabetic complications using a standardized questionnaire. 
Proliferative diabetic retinopathy was defined as history of retinal laser treatment. Data on 
smoking, defined as smoking at least one cigarette per day, were self-reported.  
 
Patients were asked to abstain from drinking tea, coffee and caffeinated beverages for 12 hours 
prior to the drawing of blood. Fasting was not required, but light, low-fat breakfast was allowed to 
treat or prevent potential hypoglycaemia. HbA1c was measured locally at each study centre using 
standardized assays. Serum triglyceride and total cholesterol concentrations (Konelab 60i; Thermo 
Fischer scientific Inc., Waltham, MA, USA), and HDL-cholesterol concentration (HTS 7000 Plus Bio; 
Perkin Elmer, Wellesley, MA, USA) were measured enzymatically. Serum creatinine concentrations 
were determined as previously described [2]. Until April 2008, serum hsCRP concentrations were 
measured with a photometric, immunochemical method (Orion Diagnostica, Espoo, Finland), and 
thereafter by immunoassay (Modular analyzer, Roche Diagnostics, Basel, Switzerland). Individuals 
with hsCRP levels >10.0 mg/l were excluded from the hsCRP analyses, as high values are 
suggestive of acute infection. Insulin sensitivity was assessed using an equation for estimated 
glucose disposal rate modified for HbA1c instead of HbA1 [13]. 
 
Renal status was assessed based on the urinary albumin excretion rate (AER). Participants were 
categorized having normal AER (<20 µg/min, or <30 mg/24h), microalbuminuria (20 µg/min ≤ AER 
<200 µg/min, or 30 mg/24h ≤ AER <300 mg/24h), or macroalbuminuria (AER ≥200 µg/min, or AER 















defined as macroalbuminuria. Based on a single measurement of serum creatinine, estimated 
glomerular filtration rate was calculated [14].  
 
Physical activity was assessed by a self-administered questionnaire on leisure-time physical activity 
[15]. The duration of the activities was multiplied by the activity- and intensity-specific metabolic 
equivalent of task (MET) to calculate the total amount of weekly leisure-time physical activity. 
Based on the sum of weekly MET hours, patients were categorized as sedentary (<10 MET 
h/week), moderately active (10-40 MET h/week), and active (>40 MET h/week).  
 
MS was defined according to the criteria by Alberti et al [16]. Accordingly, MS was assumed when 
at least three of the following criteria coexist: waist circumference ≥94 cm in men and ≥80 cm in 
women, triglyceride concentration ≥1.7 mmol/l or lipid lowering medication, HDL-cholesterol 
concentration <1.0 mmol/l in men and <1.3 mmol/l in women or medication to increase HDL-
cholesterol concentration, blood pressure ≥130/85 mmHg or use of antihypertensive medication, 
and fasting blood glucose concentration ≥110 mg/dl. In the current study, all subjects had T1D 
and, by definition, met the criterion for hyperglycaemia. A metabolic syndrome score, ranging 
between 1 and 5, was calculated for each participant, to reflect the number of fulfilled 
components of the metabolic syndrome. This score was used as a continuous variable in the 
generalized linear regression analysis. 
 
The methods to study dietary intake in the FinnDiane Study have been previously described [17]. 
In short, during the study visit, the participants completed a validated [18] diet questionnaire. This 
questionnaire intends to capture data on the participants’ habitual food intake. Of importance to 
the current study, coffee consumption was assessed using two separate questions. First, subjects 
were asked to report the number of cups of coffee consumed daily. Four categories were formed: 
non-consumers (<1 cup/d), and those with low (≥1 cups/d <3), moderate (≥3 cups/d <5), and high 
coffee consumption (≥5 cups/d). Non-consumers served as a reference group in the analyses. 
Second, the participants reported the type of coffee (filtered, boiled, instant, or other types of 
coffee) habitually consumed. 
 
After returning the diet questionnaire, participants were asked to complete a three-day exercise 















weekend day. In this record, participants reported all foods and beverages consumed, home blood 
glucose measurements, administered insulin dosages, and physical activities. With a ten-week 
interval, the record keeping was repeated to collect data from a total of six days per participant. 
The Diet 32 software (version 1.4.6.2, AIVO, Turku, Finland), and from August 2014 onwards the 
AivoDiet software (version 2.0.2.3, AIVO, Turku, Finland), based on the Finnish National Food 
Composition Database, were used to calculate energy and nutrient intakes. In the current paper, 
data were included from all participants who had completed the food record for at least three 
days. From the food record entries, the average daily energy, macronutrient, and fibre intakes 
were calculated. High alcohol intake was defined as ≥20 g/d alcohol in men and ≥10 g/d in women 
[19].  
 
Descriptive data were reported as percentages (categorical variables), mean ± standard deviation 
(parametric data), and median (interquartile range) (non-parametric data). The respective 
statistical comparisons were conducted with Chi-squared test, one-way ANOVA, and Kruskal-
Wallis test. Logistic regression analysis was used to assess associations between coffee 
consumption categories and the MS and its components. Generalized linear regression was used 
to study the association between continuous variables and coffee consumption groups. All P-
values were based on two-tailed tests. A P-value <0.05 was considered statistically significant. The 
statistical analyses were performed using IBM SPSS Statistics 22.0 for Windows (IBM Corp, 




Data from a total of 1040 participants were available for the analyses (Table 1). Of the 
participants, 13% were non-consumers, while 22%, 36% and 29% reported low, moderate, and 
high coffee intakes, respectively. The frequencies of men and smokers were the highest among 
individuals in the highest coffee category. Age and frequency of the MS increased towards the 
higher coffee consumption categories. Regarding the components of the MS, the non-consumers 
and the high intake group were the ones with the lowest and the highest frequencies of the 
triglyceride- and the HDL-components, respectively. Moreover, the frequencies of individuals 
fulfilling the blood pressure-component was observed to increase with increasing coffee 















Supplementary table 1, which shows differences in energy and alcohol (as percentages of total 
energy) intakes amongst the groups.  
 
In the logistic regression analysis, adjusted for age, sex, energy intake, alcohol intake, physical 
activity, and smoking, the odds of the MS was higher in the moderate and high coffee 
consumption groups, with non-consumers as reference (Table 2). Of the components of the MS, 
any level of coffee consumption was associated with increased odds of fulfilling the blood 
pressure-component. This association was evident also in those with no antihypertensive 
medication. Of the continuous variables, only the metabolic syndrome score was associated with 
coffee consumption (Supplementary table 2). Here, the lowest scores were observed in the non-
consumers (median, interquartile range 2.92, 2.64–3.20), and the highest scores in the high coffee 
consumption group (3.33, 3.15–3.52).  
 
The observed and the adjusted means of eGDR, eGFR and hsCRP in the four groups are shown in 
Table 3. In the final model, the mean eGFR increased towards the higher coffee consumption 
categories. In contrast, no differences were observed amongst the four groups in eGDR and hsCRP.  
 
Of the coffee consumers, 825 (91%) drank filtered coffee. Due to the small number of individuals 
reporting habitual consumption of other coffee types, they were pooled for the subsequent 
analyses. The basic characteristics of those habitually consuming filtered coffee and other types of 
coffee, were no different (data not shown). Adjusted for age, sex, smoking, energy intake, alcohol 
intake, and physical activity, consuming filtered coffee was associated with increased risk of the 
MS. However, coffee type was not associated with the odds of the individual components of the 
MS. Finally, in the fully adjusted generalized linear model, no differences were observed in eGDR, 




In general population, coffee consumption has been associated with beneficial health effects, 
including reduced risk of MS [4, 5] and type 2 diabetes [8]. As MS is frequently observed also in 
T1D [2], and since it is an independent risk factor for cardiovascular complications [3], we wanted 















risk population. In contrast to the previous observations in other populations, coffee consumption 
was associated with higher odds of MS in the current study. Particularly, compared to non-
consumers, those with moderate (≥3 cups/d <5) and high (≥5 cups/d) coffee intakes had increased 
risk of MS. Any level of coffee consumption was additionally associated with increased odds of 
fulfilling the blood pressure-component. Finally, of interest to individuals with T1D, increasing 
coffee consumption was associated with higher eGFR.  
 
The reason behind the disparity between the observations made in general population and in the 
current study is not known. Different characteristics of the study populations may offer a potential 
explanation. First, all participants in the current study had T1D and, by definition, fulfilled the 
blood glucose criterion. Moreover, compared to the healthy population, patients with T1D may 
more frequently use lipid lowering and antihypertensive medication and therefore, more often 
fulfil the lipid and the blood pressure criterion. Thus, compared to the general population, 
individuals with T1D may be more readily categorized with MS.  
 
In the current study, the association between coffee consumption and the MS seems to be mainly 
driven by the blood pressure component. Indeed, none of the other components had any 
association with habitual coffee consumption. In a previous meta-analysis, an inverse association 
between coffee consumption and hypertension was reported [20]. Analyses of potential 
confounders, in that paper, revealed smoking as a potential effect modifier in the association 
between coffee consumption and the risk of hypertension. In the current study, however, coffee 
consumption was associated with the blood pressure component of the MS independent of 
smoking. Moreover coffee, as well as insulin, has the potential to activate the sympathetic nervous 
system. Therefore, it could be speculated, that the increase seen in blood pressure with coffee 
consumption, could rather be related to an interaction between coffee and insulin dosing. Adding 
insulin in the model did, however, not change the current results, suggesting that coffee has an 
independent effect on the blood pressure.  
 
In a meta-analysis of six prospective studies, including over 170,000 individuals, an inverse J-
shaped curve was observed with the risk of hypertension increasing up to three daily cups of 
coffee, and thereafter decreasing with higher intakes [21]. The authors speculated that the pressor 















However, with increasing habitual consumption, tolerance to the caffeine-induced pressor effect 
may develop [9], thereby dissolving the blood pressure-raising effects [11]. We are unfortunately 
not aware of the coffee consumption history of the participants but the reported habitual coffee 
consumption at any level was associated with an increased risk of fulfilling the blood pressure-
component of the MS. As almost half of our population had antihypertensive medication, and thus 
fulfilled the blood pressure criterion, the results may not be directly comparable with the results 
obtained from other populations. Therefore, we repeated the analysis in a sub-population 
excluding those with antihypertensive medication. Also in this population all levels of coffee 
consumption were associated with increased odds of fulfilling the blood pressure-component.  
 
Coffee consumption was not associated with the triglyceride- or the HDL-cholesterol-components, 
in the current study. Previous results regarding coffee consumption and the serum lipid 
concentrations are somewhat inconsistent. In a large cross-sectional population-based survey, 
high coffee consumption was associated with reduced triglyceride levels [22], while in another 
study moderate coffee consumption was associated with increased triglyceride concentrations in 
men [23]. In an intervention study, however, coffee consumption did not affect the lipid profile 
[24]. The inconsistencies observed may partly be related to the differences in the types of coffee 
consumed. Indeed, boiled, unfiltered coffee contains higher amounts of coffee oils than filtered 
coffee, and has been associated with increased lipid concentrations [9]. Instead, filtered coffee 
may not affect the serum lipid levels at all [25]. In the current study, the majority of participants 
reported habitually consuming filtered coffee. Potentially due to a low number of individuals 
drinking non-filtered coffee, filtered coffee was, as seen in the whole population, associated with 
increased risk of MS. However, we were unable to detect any differences in the lipid-components 
of the MS based on the type of coffee consumed. Moreover, the current observations may not be 
directly comparable to those obtained in other populations, as individuals with T1D tend to have a 
more favourable lipid profile compared to the healthy population [26].  
 
The literature regarding the association between coffee consumption and the waist circumference 
is also inconsistent. While reports connecting coffee intake to reduced risk of obesity [9] and lower 
waist circumference have been published [22], a number of studies have reported no such 
associations [19, 26]. Our observations are in concordance with the latter studies. Proposed 















function [27] and increased energy expenditure [28]. However, based on the results from a 
Mendelian randomization study, the potential association is most likely explained by confounding 
or reverse causation, rather than by a direct biological effect [29].  
 
We calculated eGDR, as a measure of insulin sensitivity, but there was no association between 
coffee consumption and this marker. To our knowledge, no other studies have assessed the insulin 
sensitivity and coffee consumption in T1D. Interestingly, in healthy subjects, a meta-analysis of 
randomized controlled trials showed that acute caffeine ingestion reduces insulin sensitivity [30]. 
Again, the acute effects seem to differ from the long-term effects, as habitual consumption has 
been associated with reduced risk of type 2 diabetes in the general population [8]. 
  
Chlorogenic acids found in coffee are suggested to reduce subclinical inflammation via their 
antioxidative capacities [8]. As low-grade inflammation is associated with both insulin resistance 
and renal disease in T1D [31], we investigated whether habitual coffee consumption is associated 
with hsCRP and eGFR. While no clear association was observed between coffee consumption and 
hsCRP, there was an increasing trend in the eGFR with increasing coffee consumption. The 
mechanism explaining such an observation is not known. However, in concordance with our 
results, coffee consumption was also associated with higher eGFR in general population [32]. In 
that study, coffee consumption was investigated longitudinally, and as changes in eGFR or risk of 
rapid eGFR decline were not associated with coffee consumption, the authors concluded that the 
observed positive association between coffee consumption and eGFR was unlikely a result of 
glomerular hyperfiltration.  
 
One of the limitations of the study is the cross-sectional design, as such a design cannot reveal 
causalities. This study will, however, serve as a baseline for our future investigations, where the 
association between coffee consumption and health outcomes will be longitudinally assessed. 
Another limitation is the use of a self-reported questionnaire to study the coffee consumption. 
While self-reported data may be subject to recall bias, the questionnaire has been validated 
against a six-day food record and was observed to show reasonable relative validity [18]. In 
general, individuals taking part in health-related studies may be more health-conscious. This may 
limit the generalizability of our results to other individuals with T1D, at large. However, if such 















treat hypoglycaemia, a light, low-fat breakfast was accepted prior to the study visit. Of the 
components of the MS, consuming a light breakfast would most likely affect the triglyceride 
concentrations. However, as fulfilling this component of the MS also includes the use of lipid 
lowering medication, the net effect of the potential low-fat breakfast is likely moderate. While it is 
unlikely that habitual coffee consumption habits were associated with the need to eat breakfast 
prior to the study visit, the current observations need to be interpreted in the light of this 
limitation. Finally, we cannot exclude the effect of other confounding factors, which were not 
measured or controlled for in the analyses. With these limitations in mind, it should be noted that 
this is the first study to assess the association between coffee intake and MS and its components 
in individuals with T1D.  
 
In conclusion, moderate and high coffee consumption is associated with an increased risk of MS, 
while any level of coffee consumption is associated with higher odds of fulfilling the blood 
pressure-component of the MS. Moreover, increasing coffee intake is associated with higher 
eGFR. Whether habitual coffee consumption will have any negative or beneficial effects on health 
outcomes, in this population of patients with type 1 diabetes, will be assessed in future studies.  
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Table 1 Characteristics of the study population divided by coffee consumption groups (n = 1040) 
 Non-consumers 
(<1 cup/d) 
n = 134 (12.9%) 
Low consumption 
(≥1 cups/d <3) 
n = 230 (22.1%) 
Moderate consumption 
(≥3 cups/d <5) 
n = 371 (35.7%) 
High consumption 
(≥5 cups/d) 
n = 305 (29.3%) 
P 
Basic characteristics      
Men, % 34.3 32.2 45.0 59.7 <0.001 
Age, years 40 ± 13 46 ± 15 48 ± 14 49 ± 12 <0.001 
Diabetes duration, years 21 (15 – 34) 30 (17 – 41) 27 (20 – 39) 29 (20 – 38) <0.001 
HbA1c, mmol/mol 63 (56 – 72) 65 (56 – 76) 63 (56 – 71) 65 (59 – 74) 0.103 
BMI, kg/m
2
 25.8 (23.2 – 28.3) 25.7 (23.1 – 28.4) 25.3 (23.4 – 28.4) 25.7 (23.4 – 28.3) 0.927 
Retinopathy, % 23 38 28 32 0.021 
Diabetic nephropathy, % 6 9 11 12 0.232 
eGFR, ml/min 120 (110 – 129) 115 (99 – 127) 111 (96 – 123) 107 (96 – 118) <0.001 
eGDR, mg/kg/min 7.1 (4.5 – 8.8) 5.2 (4.0 – 8.3) 5.4 (4.1 – 7.9) 4.9 (3.6 – 7.5) <0.001 
hsCRP, mg/l 1.19 (0.56 – 2.91) 1.31 (0.60 – 2.50) 0.97 (0.48 – 2.29) 0.91 (0.45 – 2.10) 0.033 
Physical activity     0.442 
  Sedentary, % 26 33 31 28  
  Moderately active, % 52 51 55 52  
  Active, % 22 16 14 20  
Current smoking, % 3 10 12 22 <0.001 
Antihypertensive medication, % 31 53 48 53 <0.001 
Lipid-lowering medication, % 23 35 33 43 0.001 
Components of the metabolic 
syndrome  
     
Metabolic syndrome, % 51 64 65 70 0.002 
Waist component, % 56 55 55 57 0.966 
Waist circumference, cm      
  Men 89 (84 – 97) 93 (86 – 101) 93 (86 – 100) 94 (87 – 103) 0.084 
  Women 84 (77 – 96) 83 (75 – 93) 83 (76 – 92) 82 (77 – 89) 0.544 
Triglyceride component, % 34 43 40 50 0.011 
Triglyceride, mmol/l 0.92 (0.72 – 1.19) 0.99 (0.75 – 1.39) 0.89 (0.70 – 1.26) 1.01 (0.77 – 1.36) 0.012 















HDL, mmol/l      
  Men 1.39 (1.17 – 1.61) 1.50 (1.17 – 1.80) 1.53 (1.28 – 1.77) 1.41 (1.16 – 1.68) 0.022 
  Women 1.70 (1.32 – 1.94) 1.72 (1.42 – 2.09) 1.76 (1.42 – 2.04) 1.62 (1.40 – 2.06) 0.572 
BP component, % 57 78 79 83 <0.001 
Systolic BP, mmHg 128 (119 – 141) 135 (122 – 151) 137 (127 – 150) 137 (127 – 148) <0.001 
Diastolic BP, mmHg 76 ± 9 77 ± 10 77 ± 9 78 ± 9 0.509 
 Data are presented as percentages for categorical variables, mean ± standard deviation for continuous normally distributed variables, and median (interquartile 
range) for continuous non-normally distributed variables. Respective statistical comparisons amongst the four groups were conducted with Chi-squared test, 
ANOVA, and Kruskal-Wallis test. BMI, body mass index; eGFR, estimated glomerular filtration rate; eGDR, estimated glucose disposal rate; hsCRP, high-sensitivity 
C-reactive protein; physical activity level, sedentary (weekly MET h <10), moderately active (≥10 and ≤40), active (weekly MET h >40); HDL, high-density 
























Table 2 Associations between coffee consumption categories and the metabolic syndrome and its components 
Outcome variable Model Non-consumers 
(<1 cup/d) 
Low consumption 
(≥1 cups/d <3) 
Moderate consumption 
(≥3 cups/d <5) 
High consumption 
(≥5 cups/d) 
Metabolic syndrome M1 1 1.61 (0.96 – 2.70) 1.40 (0.87 – 2.56) 2.07 (1.24 – 3.45)** 
 M2 1 1.56 (0.86 – 2.83) 1.76 (1.02 – 3.06)* 2.13 (1.17 – 3.87)*  
Waist circumference component M1 1 0.89 (0.54 – 1.47) 0.96 (0.60 – 1.52) 1.12 (0.69 – 1.83) 
 M2 1 0.91 (0.51 – 1.63) 1.19 (0.70 – 2.05) 1.17 (0.66 – 2.08) 
Triglyceride component M1 1 1.35 (0.79 – 2.33) 0.92 (0.55 – 1.53) 1.46 (0.86 – 2.46) 
 M2 1 1.44 (0.76 – 2.73) 1.01 (0.55 – 1.83) 1.65 (0.88 – 3.07) 
Triglyceride component
1
 M1 1 1.04 (0.42 – 2.54) 0.58 (0.24 – 1.42) 0.79 (0.31 – 2.03) 
 M2 1 1.10 (0.38 – 3.21) 0.56 (0.19 – 1.65) 0.69 (0.21 – 2.24) 
HDL-cholesterol component M1 1 1.39 (0.81 – 2.39) 1.13 (0.68 – 1.87) 1.86 (1.10 – 3.14)* 
 M2 1 1.34 (0.71 – 2.53) 1.19 (0.66 – 2.15) 1.84 (0.99 – 3.42) 
HDL-cholesterol component
1
 M1 1 0.93 (0.36 – 2.38) 1.17 (0.50 – 2.75) 1.62 (0.65 – 4.04) 
 M2 1 0.76 (0.24 – 2.35) 1.18 (0.43 – 3.22) 0.92 (0.28 – 3.04) 
Blood pressure component M1 1 2.67 (1.47 – 4.89)** 2.01 (1.18 – 3.44)* 2.05 (1.14 – 3.69)* 
 M2 1 2.80 (1.40 – 5.62)** 2.40 (1.29 – 4.48)** 2.19 (1.08 – 4.44)* 
Blood pressure component
2
 M1 1 2.66 (1.31 – 5.39)** 2.31 (1.22 – 4.36)* 2.51 (1.27 – 4.94)** 
 M2 1 2.48 (1.09 – 5.67)* 2.43 (1.17 – 5.05)* 2.31 (1.03 – 5.18)* 
Data are presented as odds ratio (95% confidence interval). Logistic regression analysis. Model 1, adjusted for age, sex, and energy intake; Model 2, additionally 
adjusted for alcohol intake, physical activity, and smoking status. * p<0.05, ** p<0.01, 
1 























Table 3 Associations between coffee consumption categories and eGDR, eGFR, and hsCRP 
Outcome variable Model Non-consumers 
(<1 cup/d) 
Low consumption 
(≥1 cups/d <3) 
Moderate consumption 




eGDR M1 7.1 (6.6 – 7.5) 5.9 (5.6 – 6.3) 6.0 (5.7 – 6.2) 5.5 (5.2 – 5.8) <0.001 
 M2 6.4 (6.0 – 6.8) 5.7 (5.4 – 6.0) 6.0 (5.8 – 6.3) 5.8 (5.6 – 6.1) 0.189 
 M3 6.4 (6.0 – 6.8) 5.8 (5.5 – 6.1) 6.0 (5.8 – 6.3) 5.8 (5.6 – 6.1) 0.180 
eGFR M1 116.8 (112.4 – 121.3) 110.0 (106.5 – 113.4) 107.4 (104.8 – 110.1) 104.2 (101.3 – 107.2) <0.001 
 M2 106.4 (103.2 – 109.6) 106.8 (104.4 – 109.2) 108.6 (106.7 – 110.4) 109.8 (107.7 – 111.9) 0.036 
 M3 105.8 (103.1 – 108.4) 107.2 (105.1 – 109.2) 108.4 (106.9 – 110.0) 109.9 (108.2 – 111.7) 0.006 
hsCRP M1 2.04 (1.67 – 2.41) 1.96 (1.68 – 2.34) 1.61 (1.40 – 1.82) 1.58 (1.35 – 1.82) 0.009 
 M2 1.91 (1.54 – 2.28) 1.91 (1.63 – 2.19) 1.61 (1.41 – 1.82) 1.67 (1.43 – 1.90) 0.124 
 M3 1.93 (1.56 – 2.30) 1.88 (1.61 – 2.16) 1.62 (1.41 – 1.82) 1.68 (1.44 – 1.91) 0.135 
Data are presented as mean (95% Wald Confidence Interval). Generalized linear model. eGDR, estimated glucose disposal rate; eGFR, estimated glomerular 
filtration rate; hsCRP, high-sensitivity C-reactive protein. Model 1, unadjusted; Model 2, adjusted for age and sex; Model 3, adjusted for age, sex, nephropathy 



























• Coffee intake has been associated with health benefits in the general population 
• Whether coffee exerts health benefits also in type 1 diabetes is not known  
• High coffee consumption was associated with higher odds of metabolic syndrome 
• All coffee intake levels were associated with increased risk of blood pressure component 
• An increasing trend between eGFR and coffee consumption was observed 
 
 
